Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Plasticell completes £1.32 million financing to advance therapeutic projects

Plasticell
Posted on: 04 Nov 16

Stevenage, UK, 4 November 2016

 

Plasticell, the biotechnology company specialising in cell and gene therapy research, announces the completion of a two-part equity financing round, raising a total of £1.32 million from its shareholders and new investors.

 

The investment will provide capital to progress the company’s therapeutic programmes, including the expansion of hematopoietic stem cells and in vitro manufacturing of blood products such as platelets, red blood cells and cancer immunotherapies.

 

Plasticell specialises in using massively parallel screening technologies to optimise high value cell therapies derived from stem cells. Its award-winning platform technology, CombiCult®, can be applied to any cell culture process, including biopharmaceutical production, as well as cell and gene therapy manufacturing.

 

Plasticell’s lead therapeutic programme is in the expansion of hematopoietic stem cells derived from bone marrow and cord blood. Last year the company announced it received a grant of approximately £1.3 million from Innovate UK to develop GMP manufacturing for this therapy in collaboration with the University of Oxford and the Cell and Gene Therapy Catapult over three-years.

 

Dr Yen Choo, Executive Chairman of Plasticell, commented: “Together with non-dilutive financing from multiple government grants, this latest equity fundraising provides the capital required to progress our lead therapeutic programme towards the clinic.”

 

-ENDS-

 

About Plasticell

 

Plasticell is a biotechnology company that specialises in using massively parallel screens to optimize cell culture, including the differentiation of stem cells and the manufacture of cell and gene therapies.

 

Its proprietary technology, Combinatorial Cell Culture™ (CombiCult®), allows Plasticell to test a massive number of cell culture variables in random combinations to discover optimal laboratory protocols for any given outcome in cell biology.

 

Plasticell uses its technology to develop cell and gene therapies. In addition Plasticell forms strategic alliances with industry partners to facilitate drug discovery cell and gene therapy applications.

 

For more information visit the Plasticell website: www.plasticell.co.uk

 

For media enquiries, please contact Tristan Jervis on +44 203 735 8166, t.jervis@defacto.com or Alex Heeley, a.heeley@defacto.com +44 203 735 8168

 

Editor's Details

Tristan Jervis
De Facto Communications
www.defacto.com
203 735 8166
T.jervis@defacto.com

Last updated on: 04/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.